ImmunityBio’s Shareholder Settlement Gains Preliminary Approval

ImmunityBio ( (IBRX) ) has shared an update.

On July 29, 2025, the United States District Court for the Southern District of California preliminarily approved a proposed settlement of shareholder derivative actions against ImmunityBio‘s individual defendants. The settlement includes corporate governance reforms and attorneys’ fees covered by insurance, with a final approval hearing set for November 4, 2025. The derivative actions alleged breaches of fiduciary duties and misleading statements by ImmunityBio’s officers regarding manufacturing practices, impacting the company’s stock price and leading to a related securities fraud class action.

The most recent analyst rating on (IBRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

Spark’s Take on IBRX Stock

According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.

ImmunityBio’s financial difficulties and negative valuation metrics are the most significant factors weighing on the score. However, recent corporate events, including new financing and revenue growth, provide a glimmer of hope for future improvement. Technical analysis provides a neutral outlook, indicating no immediate risks or opportunities.

To see Spark’s full report on IBRX stock, click here.

More about ImmunityBio

ImmunityBio is a biotechnology company focused on developing next-generation therapies and vaccines that enhance the natural immune system to combat cancers and infectious diseases. Its lead product, Anktiva, is an IL-15 agonist antibody-cytokine fusion protein, which was approved by the FDA in April 2024 for treating BCG-unresponsive non-muscle invasive bladder cancer.

Average Trading Volume: 8,708,973

Technical Sentiment Signal: Sell

Current Market Cap: $2.25B

Learn more about IBRX stock on TipRanks’ Stock Analysis page.